LB PHARMACEUTICALS INC
LB PHARMACEUTICALS INC (LBRX): 1 pipeline candidate · 5 upcoming catalysts · ~48 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
47.8 months
D/E 0.04 · 0% dilution
Lead: Phase 2
1 candidate
5 upcoming, next in ~470d
2 buys · 0 sells (180d)
A transparent, data-derived signal for LB PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$817.3M
Cash
$321.5M
Quarterly Burn
$23.3M
Runway
47.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| lb-102 | Phase 2 |
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
72
Total value held
$566.1M
| Holder | Shares | Value |
|---|---|---|
| deep track capital, lp | 3,352,804 | $82.7M |
| blackrock, inc. | 2,470,845 | $60.9M |
| ra capital management, l.p. | 2,208,604 | $54.5M |
| vanguard capital management llc | 1,789,306 | $44.1M |
| vivo capital, llc | 1,600,000 | $39.5M |
| commodore capital lp | 1,500,000 | $37.0M |
| caligan partners lp | 1,438,070 | $34.6M |
| balyasny asset management l.p. | 923,694 | $22.8M |
| logos global management lp | 915,000 | $22.6M |
| alyeska investment group, l.p. | 863,947 | $21.3M |
Showing top 10 of 72 institutional holders of LB PHARMACEUTICALS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in LB PHARMACEUTICALS INC's pipeline?
LB PHARMACEUTICALS INC (LBRX) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is LB PHARMACEUTICALS INC's lead drug candidate?
LB PHARMACEUTICALS INC's most advanced tracked candidate is lb-102 (Phase 2) for Schizophrenia; Bipolar I Disorder.
What is LB PHARMACEUTICALS INC's next catalyst?
LB PHARMACEUTICALS INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate the Antipsychotic Ef" — expected October 1, 2027.
What is LB PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, LB PHARMACEUTICALS INC has approximately 47.8 months of cash runway.
What is LB PHARMACEUTICALS INC's market capitalization?
LB PHARMACEUTICALS INC's market capitalization is approximately $817.3M.
Get the full picture on LB PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.